b
r
c
background
purpos
celastrol
quinon
methid
triterpen
isol
root
extract
tripterygium
wilfordii
greatli
induc
gene
express
activ
heme
achiev
diseas
prevent
control
induct
recent
shown
result
antihcv
activ
induc
type
interferon
inhibit
hepat
c
viru
hcv
proteas
activ
aim
present
studi
evalu
antihcv
activ
celastrol
character
mechan
inhibit
method
antihcv
activ
celastrol
evalu
use
hcv
subgenom
replicon
hcvcc
infect
system
antihcv
mechan
celastrol
target
express
clarifi
use
specif
inhibitor
sever
signal
pathway
transcript
regul
celastrol
target
gene
express
determin
use
promoterbas
report
activ
assay
synergist
effect
celastrol
number
clinic
use
antihcv
drug
determin
via
drug
combin
assay
result
celastrol
inhibit
hcv
replic
hcv
subgenom
hcvcc
infect
system
valu
mm
respect
celastrolinduc
heme
oxygenas
express
promot
antivir
interferon
respons
inhibit
proteas
activ
therebi
block
hcv
replic
antivir
effect
abrog
treatment
inhibitor
snmp
silenc
express
transfect
shrna
indic
induct
contribut
antihcv
activ
celastrol
jnk
mitogenactiv
protein
kinas
nuclear
factor
erythroid
factor
confirm
involv
induct
effect
celastrol
express
celastrol
exhibit
synergist
effect
combin
interferonalpha
inhibitor
daclatasvir
inhibitor
sofosbuvir
conclus
celastrol
serv
potenti
supplement
block
hcv
replic
target
axi
present
promis
strategi
hcv
infect
hepat
c
viru
hcv
envelop
singlestrand
positivesens
rna
viru
belong
hepaciviru
genu
flavivirida
famili
brass
et
al
genom
viru
includ
base
pair
encod
structur
protein
c
nonstructur
protein
brass
et
al
hcv
infect
risk
factor
chronic
liver
diseas
includ
cirrhosi
fibrosi
hepatocellular
carcinoma
hcvinfect
patient
estim
number
million
worldwid
alter
past
standard
care
soc
hcv
infect
treatment
combin
pegyl
interferon
pegifna
ribavirin
rbv
howev
efficaci
treatment
patient
infect
genotyp
hcv
ghani
et
al
well
soc
therapi
associ
sever
advers
effect
anemia
headach
fatigu
depress
schoggin
et
al
telaprevir
boceprevir
first
daa
approv
us
food
drug
administr
fda
found
exhibit
higher
rate
sustain
virolog
respons
svr
patient
infect
genotyp
hcv
combin
pegifna
provid
new
soc
treatment
chronic
hcv
infect
kiser
et
al
despit
increas
efficaci
treatment
mode
develop
hcv
infect
howev
undesir
side
effect
continu
observ
therapi
kiser
et
al
fda
recent
approv
twoagent
combo
harvoni
fourag
combo
viekira
pak
distribut
treatment
could
achiev
svr
patient
infect
genotyp
hcv
koretz
unfortun
antivir
agent
achiev
higher
rate
svr
avoid
advers
effect
often
induc
ifn
koretz
also
exist
risk
reactiv
hepat
b
viru
hbv
treat
patient
hcv
hbv
coinfect
yeh
et
al
moreov
two
drug
rel
expens
drug
thu
develop
safeti
costeffect
substitut
treatment
import
endeavor
celastrol
quinon
methid
triterpen
isol
tripterygium
wilfordii
medicin
plant
use
treat
rang
ill
includ
inflamm
swell
fever
sore
pain
india
japan
china
korea
asian
countri
ju
et
al
lee
jy
et
al
youn
et
al
celastrol
meal
supplement
wide
use
herbal
medicin
divers
biolog
activ
includ
antiinflamm
anticanc
hepatoprotect
antimicrobi
properti
ju
et
al
lee
et
al
sever
report
demonstr
celastrol
exhibit
inhibitori
effect
human
immunodefici
viru
youn
et
al
dengu
viru
yu
et
al
sever
acut
respiratori
syndromeassoci
coronavirus
ryu
et
al
celastrol
induc
heme
gene
express
via
nuclear
factor
erythroid
factor
activ
prevent
circulatori
failur
prevent
protect
myocardi
ischemia
der
sarkissian
et
al
induct
recent
shown
result
antihcv
activ
induc
type
interferon
inhibit
hcv
proteas
activ
lehmann
et
al
zhu
et
al
induc
ratelimit
enzym
degrad
heme
produc
biliverdin
carbon
monoxid
co
ferrou
iron
via
heme
catabol
pathway
main
enzym
metabolit
exhibit
protect
effect
oxid
stressinduc
tissu
damag
upon
exposur
multipl
stimuli
viral
bacteri
product
includ
lipopolysaccharid
cytokin
oncogen
mitogen
variou
growth
factor
farombi
surh
pain
et
al
upon
hcv
infect
downregul
express
observ
hcvinfect
patient
hcv
core
protein
express
although
biolog
role
suppress
detail
mechan
hcv
express
unclear
abdalla
et
al
detoxifi
enzym
mainli
regul
et
al
activ
express
occur
bind
antioxid
respons
element
promot
region
contrast
suppress
express
compet
bind
site
et
al
normal
condit
sequest
cytoplasm
kelchlik
echassoci
protein
mediat
proteasom
degrad
et
al
upregul
express
achiev
antiinflammatori
antioxid
stress
function
mediat
sever
host
factor
includ
mitogeneactiv
protein
kinas
mapk
molecul
mapk
extracellular
signalregul
kinas
cjun
ntermin
kinas
jnk
pain
et
al
studi
data
reveal
celastrol
significantli
inhibit
hcv
replic
antihcv
effect
celastrol
attenu
specif
inhibitor
tin
mesoporphyrin
snmp
gene
express
silenc
celastrolmedi
induct
contribut
antihcv
action
induc
antivir
ifn
respons
inhibit
hcv
proteas
activ
moreov
axi
critic
pathway
involv
celastrolmedi
induct
hcv
replic
combin
celastrol
ifna
sofosbuvir
daclatasvir
test
determin
abil
enhanc
antihcv
activ
human
hepatoma
cell
contain
hcv
genotyp
subgenom
rna
replicon
cell
blight
et
al
cell
harbor
hcv
genotyp
subgenom
rna
renilla
luciferas
report
gene
obtain
apath
llc
st
loui
mo
maintain
dulbecco
modifi
eagl
medium
contain
fetal
bovin
serum
nonessenti
amino
acid
antibioticeantimycot
co
atmospher
c
cell
stabli
express
plasmid
grown
produc
cell
culturederiv
infecti
hcv
particl
hcvcc
condit
medium
collect
harvest
viral
particl
accord
protocol
describ
previous
kato
et
al
celastrol
purchas
fusolmateri
co
ltd
tainan
taiwan
roferon
purchas
roch
ltd
specif
inhibitor
tin
mesoporphyrin
snmp
mapkspecif
inhibitor
purchas
sigma
st
loui
mo
daclatasvir
sofosbuvir
purchas
shanghai
haoyuan
chemexpress
co
ltd
final
concentr
dmso
reaction
maintain
cell
seed
plate
densiti
cell
per
well
treat
celastrol
indic
concentr
day
incub
cell
viabil
determin
celltit
aq
ueou
one
solut
cell
prolifer
assay
promega
madison
wi
usa
accord
manufactur
instruct
hillkapturczak
et
al
liao
et
al
vector
use
measur
transcript
activ
respect
pisreluc
report
vector
contain
firefli
luciferas
control
ifnstimul
respons
element
isr
use
measur
ifn
responsedepend
transcript
activ
stratagen
agil
technolog
ca
usa
clone
dna
fragment
verifi
dna
sequenc
western
blot
perform
describ
previous
lee
et
al
brief
mg
cell
lysat
analyz
sdspage
transfer
pvdf
membran
membran
probe
antihcv
abcam
cambridg
usa
abcam
genetex
ca
usa
cell
signal
technolog
inc
danver
usa
cell
signal
antiphosphojnk
cell
signal
cell
signal
cell
signal
antijnk
cell
signal
antibodi
load
control
determin
use
antigapdh
antibodi
genetex
rna
isol
quantit
realtim
rtpcr
qrtpcr
perform
describ
previous
lee
et
al
rel
mrna
level
determin
normal
cellular
endogen
dehydrogenas
gapdh
gene
primer
use
studi
list
tabl
evalu
transcript
regul
ifn
respons
celastrol
cell
seed
plate
densiti
cell
per
well
h
incub
mg
promoterdriven
firefli
luciferas
plasmid
includ
pisreluc
respect
transfect
preseed
cell
use
transfect
reagent
jifeng
biotechnolog
co
ltd
taiwan
accord
manufactur
instruct
transfect
cell
treat
celastrol
variou
concentr
day
cell
lysat
prepar
luciferas
activ
assay
western
blot
use
brightglo
luciferas
assay
system
promega
madison
wi
usa
cellbas
activ
assay
perform
describ
previous
lee
et
al
brief
cell
seed
plate
densiti
cell
per
well
h
incub
cell
cotransfect
proteas
report
vector
peg
seap
express
vector
follow
celastrol
treatment
without
snmp
day
mm
telaprevir
treatment
server
posit
control
supernat
harvest
seap
activ
assay
use
phosphalight
assay
kit
transfect
mixtur
contain
mg
firefli
luciferas
express
vector
pfluc
transfect
control
normal
seap
activ
cell
seed
plate
densiti
cell
well
treat
variou
concentr
celastrol
day
cell
cultur
medium
harvest
measur
ifna
concentr
use
human
ifna
elisa
kit
uscnk
life
scienc
inc
usa
accord
manufactur
protocol
absorb
detect
nm
use
epoch
micropl
spectrophotomet
cell
seed
dish
densiti
cell
per
dish
treat
increas
concentr
celastrol
day
cell
collect
prepar
nuclear
fraction
describ
previous
lee
et
al
cell
treat
serial
dilut
celastrol
mm
combin
serial
dilut
ifna
uml
telaprevir
mm
sofosbuvir
nm
daclatasvir
pm
day
incub
hcv
rna
level
determin
qrtpcr
multipl
drug
combin
data
analyz
use
softwar
biosoft
cambridg
uk
compar
singl
multipl
drug
dose
effect
determin
combin
index
ci
valu
effect
multipl
drug
combin
present
antagon
ci
addit
ci
synerg
ci
data
present
mean
standard
deviat
least
three
independ
experi
statist
signific
analyz
use
student
ttest
signific
differ
consid
p
celastrol
quinon
methid
triterpen
fig
possess
antidenv
activ
lee
et
al
discov
whether
celastrol
exhibit
antihcv
activ
first
treat
hcv
subgenom
replicon
cell
celastrol
increas
concentr
day
western
blot
assay
qrtpcr
analysi
perform
determin
hcv
protein
rna
level
celastrol
treatment
respect
cytotox
effect
celastrol
cell
also
test
use
mt
assay
result
indic
celastrol
dosedepend
reduc
hcv
protein
synthesi
fig
rna
replic
effect
concentr
ec
mm
fig
without
cytotox
effect
antivir
concentr
cytotox
concentr
cc
mm
fig
base
result
collect
hcv
replicon
select
index
celastrol
hcv
replic
approxim
replicon
hcvcc
infecti
assay
perform
confirm
antihcv
activ
celastrol
replicon
cell
cell
treat
increas
concentr
celastrol
day
shown
fig
f
qrtpcr
analysi
reveal
celastrol
dosedepend
reduc
hcv
rna
level
fulli
inhibit
hcv
replic
concentr
mm
celastrol
recent
shown
induc
gene
express
antivir
activ
youn
et
al
first
examin
whether
celastrol
could
induc
express
determin
promot
activ
well
rna
protein
level
cell
presenc
celastrol
cell
transfect
contain
firefli
luciferas
gene
driven
promot
transfectedcel
treat
celastrol
increas
concentr
day
subject
luciferas
activ
assay
result
indic
celastrol
significantli
induc
promot
activ
concentrationdepend
manner
fig
expect
rna
protein
level
also
dosedepend
induc
celastrol
fig
c
investig
whether
celastrolinduc
express
involv
antihcv
activ
celastrol
cell
cotreat
fix
concentr
celastrol
increas
concentr
specif
inhibitor
snmp
day
western
blot
assay
preform
determin
restor
effect
snmp
hcv
protein
synthesi
upon
celastrol
treatment
shown
fig
celastrol
inhibit
hcv
protein
synthesi
compar
noncelastrol
treat
cell
lane
contrast
snmp
treatment
dosedepend
attenu
suppress
effect
celastrol
hcv
protein
synthesi
lane
expect
specif
shrna
mediat
gene
silenc
also
attenu
suppress
effect
celastrol
hcv
protein
synthesi
fig
result
reveal
celastrol
inhibit
hcv
replic
correl
induct
result
qrtpcr
analysi
indic
rna
level
gradual
induc
celastrol
fig
contrast
induct
effect
celastrol
rna
level
significantli
attenu
inhibitor
snmp
concentrationdepend
manner
fig
next
measur
ifna
protein
secret
level
cultur
medium
celastrol
treatment
expect
elisa
result
indic
ifna
protein
secret
level
gradual
induc
celastrol
day
treatment
fig
antivir
effect
cell
may
attribut
interact
ifna
cell
surfac
ifna
receptor
lead
activ
isr
upregul
downstream
antivir
gene
yu
et
al
evalu
whether
celastrolinduc
ifna
could
activ
downstream
antivir
gene
isr
activ
express
three
critic
ifnmedi
antivir
gene
includ
oligoadenyl
synthetas
measur
cell
transfect
isredriven
firefli
luciferas
report
plasmid
follow
treatment
celastrol
day
luciferas
assay
result
indic
isr
promot
activ
increas
approxim
celastrol
fig
gene
express
level
significantli
upregul
approxim
celastrol
respect
fig
anoth
propos
antihcv
action
induct
inhibit
proteas
activ
zhu
et
al
therefor
perform
cellbas
hcv
proteas
assay
examin
abil
celastrol
target
hcv
proteas
activ
cell
cotransfect
peg
seap
report
hcv
proteas
express
plasmid
follow
celastrol
treatment
day
shown
fig
hcv
proteas
activ
decreas
approxim
comparison
control
celastrol
contrast
inhibitori
effect
celastrol
hcv
proteas
activ
dosedepend
attenu
inhibitor
snmp
fig
data
indic
target
hcv
proteas
altern
antihcv
action
celastrol
function
import
upstream
regul
mediat
express
bind
respons
element
farombi
surh
investig
whether
celastrolinduc
induct
mediat
activ
first
investig
nuclear
transloc
cell
treat
increas
concentr
celastrol
day
total
cell
lysat
nuclear
fraction
harvest
subject
western
blot
assay
shown
fig
total
protein
level
affect
celastrol
upper
panel
contrast
nuclear
protein
level
significantli
accumul
upon
celastrol
treatment
concentr
mm
effect
dosag
hcv
replic
examin
activ
caus
celastrol
cell
transfect
aredriven
firefli
luciferas
report
plasmid
transfectedcel
treat
increas
concentr
celastrol
day
expect
aredriven
firefli
luciferas
activ
elev
celastrol
concentrationdepend
manner
fig
consid
result
axi
conclud
strongli
associ
antihcv
activ
celastrol
activ
mapk
signal
cascad
includ
jnk
report
involv
induct
result
antihcv
activ
huang
et
al
whether
mapk
involv
antihcv
effect
celastrol
cell
treat
mm
celastrol
min
phosphoryl
level
jnk
measur
western
blot
phosphospecif
antibodi
cell
incub
celastrol
day
total
cell
lysat
cellular
nuclear
fraction
harvest
total
nuclear
ne
level
analyz
western
blot
use
antibodi
lamin
serv
intern
control
nuclear
fraction
gapdh
serv
intern
control
total
cell
lysat
b
celastrol
increas
transactiv
cell
transfect
mg
follow
celastrol
treatment
day
harvest
analyz
luciferas
activ
luciferas
activ
use
repres
isr
activ
error
bar
denot
mean
sd
three
independ
experi
p
shown
fig
jnk
phosphoryl
level
elev
celastrol
timedepend
manner
compar
time
point
min
contrast
celastrol
show
signific
effect
phosphoryl
time
point
clarifi
role
jnk
induct
celastrol
use
specif
inhibitor
jnk
measur
rna
express
shown
fig
rna
express
level
induc
celastrol
compar
noncelastrol
treat
cell
jnk
inhibitor
significantli
reduc
induct
effect
celastrol
contrast
inhibitor
inhibitor
show
signific
effect
celastrolinduc
induct
result
suggest
antihcv
effect
celastrol
associ
jnkmediat
induct
cell
celastrol
synergist
addit
inhibit
hcv
replic
combin
ifna
sofosbuvir
daclatasvir
telaprevir
determin
whether
celastrol
enhanc
antihcv
activ
sever
clinic
use
antihcv
drug
ifna
inhibitor
telaprevir
inhibitor
sofosbuvir
lam
et
al
inhibitor
daclatasvir
lee
et
al
cell
cotreat
drug
celastrol
variou
concentr
ratio
day
synergist
effect
combin
evalu
calcusyn
describ
chou
talalay
ci
valu
ec
ec
ec
ifna
rang
telaprevir
rang
sofosbuvir
rang
daclatasvir
rang
tabl
signific
cytotox
observ
combin
treatment
assess
colorimetr
mt
assay
data
shown
find
reveal
celastrol
may
serv
dietari
supplement
enhanc
therapeut
effect
clinic
use
antihcv
drug
type
ifn
system
present
import
innat
immun
effect
block
viru
replic
jone
et
al
morrison
et
al
hcv
infect
report
inhibit
antivir
ifn
respons
facilit
viru
replic
promot
hcv
proteasemedi
cleavag
mitochondri
antiviralsign
protein
mav
tirdomaincontain
adapterinduc
interferonb
trif
gokhal
et
al
present
studi
found
natur
product
celastrol
could
effect
inhibit
hcv
proteas
activ
enhanc
ifnmedi
antivir
gene
express
induct
fig
metabolit
biliverdin
proven
blocker
hcv
proteas
activ
therefor
regulatori
effect
celastrol
mitochondriamedi
inf
signal
pathway
viru
replic
present
promis
prospect
futur
investig
data
reveal
induct
contribut
antihcv
activ
celastrol
base
accumul
nuclear
enhanc
bind
activ
respons
element
fig
given
activ
nuclear
transloc
regul
ubiquitin
competitor
bind
promot
region
main
futur
studi
perform
determin
whether
celastrol
alter
express
level
regul
induct
knowledg
area
help
provid
altern
target
screen
antihcv
agent
found
induct
effect
celastrol
also
associ
jnk
activ
fig
howev
sever
kinas
involv
jnk
activ
includ
mitogenactiv
protein
kinas
kinas
mixedlineag
kinas
mlk
wasserman
et
al
futur
studi
examin
effect
celastrol
kinas
involv
jnk
activ
comprehens
describ
relationship
celastrol
induct
sever
studi
indic
celastrol
exhibit
antiinflammatori
activ
inhibit
nuclear
factorkb
nfkb
downstream
ding
et
al
joshi
et
al
basi
earlier
find
promis
tactic
hcv
infect
via
downregul
nfkbmediat
express
lee
et
al
propos
inhibitori
effect
celastrol
nfkbmediat
express
may
least
part
contribut
antihcv
activ
henc
work
necessari
elucid
addit
signal
pathway
involv
antihcv
activ
celastrol
drug
combin
therapi
consid
promis
approach
increas
therapeut
efficaci
decreas
drug
resist
comparison
monodrug
therapi
hajj
et
al
twoagent
combo
harvoni
fourag
combo
viekira
pak
could
achiev
svr
patient
infect
genotyp
hcv
howev
low
fidel
hcv
polymeras
viral
replic
may
lead
emerg
drug
resist
pose
major
challeng
treat
hcv
infect
lee
et
al
target
host
factor
could
altern
strategi
elimin
drug
resist
hcv
therapeut
regimen
mutat
rate
host
genom
lower
rna
viru
genom
liao
et
al
studi
show
celastrol
consid
suitabl
candid
hcv
therapi
minim
risk
drug
resist
target
host
signal
pathway
synergist
inhibit
hcv
replic
combin
clinic
use
drug
differ
viral
target
tabl
studi
warrant
clarifi
potenti
clinic
relev
find
summari
data
indic
celastrol
effici
inhibit
hcv
replic
via
induct
axi
may
repres
therapeut
target
futur
develop
discoveri
antihcv
drug
celastrol
exhibit
synerget
effect
antihcv
activ
combin
ifn
sofosbuvir
daclatasvir
result
reveal
celastrol
may
serv
dietari
supplement
enhanc
therapeut
effect
antihcv
drug
current
avail
